# Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Canonical URL: https://biopharmsignal.com/news/CLRB/cellectar-biosciences-reports-first-quarter-2026-financial-results-and-provides-corporate-updates
Ticker: CLRB
Company: Cellectar Biosciences
Source: Cellectar Biosciences
Published: 2026-05-14 11:15 EST
Original Source URL: https://www.cellectar.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-15 11:30 EST — [Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-announces-publication-of-phase-1-study-of-iopofosine-i-131-1d5d4326) — Source: Cellectar Biosciences
- 2026-06-01 12:05 EST — [Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-to-highlight-compelling-new-efficacy-data-from-phase-2b-clover-wam-study-of-iopofosine-i-131-in-r-r-waldenstroem-macroglobulinemia-at-the-american-society-of-clinical-oncology-annual-meeting) — Source: Cellectar Biosciences
- 2026-05-14 11:15 EST — [Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-reports-first-quarter-2026-financial-results-and-provides-corporate-updates) — Source: Cellectar Biosciences
- 2026-05-11 12:05 EST — [Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-to-report-first-quarter-financial-results-and-host-a-conference-call-on-thursday-may-14-2026) — Source: Cellectar Biosciences
- 2026-05-05 11:10 EST — [Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-reports-positive-12-month-follow-up-data-from-phase-2b-clover-wam-study-demonstrating-durable-responses-and-efficacy-of-iopofosine-i-131-in-r-r-waldenstroem-macroglobulinemia) — Source: Cellectar Biosciences
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)